Kvantra
Kvantra
Log inSign up for Free
Log inSign up for Free
Stock profile

Scilex Holding Company(SCLX)

Country: United States of AmericaSector: HealthcareIndustry: Drug Manufacturers - GeneralExchange: NASDAQ
Watchlist
Sign up to track this stock
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
57.68M
Currency USD
KvantraRanki35
Value4
Quality94
Momentum2
Current price
6.74-2.32%
Benchmarks

No price history available.

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m243138475730N/AN/A
Operating profit$mLockedLockedLockedLockedLockedLockedLockedLocked
Net profit$m-48-88-23-114-73-359N/AN/A
EPS reported$LockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per share$LockedLockedLockedLockedLockedLockedLockedLocked
Capex per share$LockedLockedLockedLockedLockedLockedLockedLocked
FCF per share$LockedLockedLockedLockedLockedLockedLockedLocked
Free cash flow$mLockedLockedLockedLockedLockedLockedLockedLocked
Net debt$mLockedLockedLockedLockedLockedLockedLockedLocked
Book value equity$mLockedLockedLockedLockedLockedLockedLockedLocked
Book value per share$LockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)$LockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Price target estimates

Low estimateLocked
High estimateLocked
Price consensusLocked
Last year average price targetLocked
Current price6.74
Return PotentialLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked

Company overview

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States of America
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Scilex Holding Company (SCLX)

SCLX · NASDAQ · Healthcare
6.74-2.32%
Sign up to track this stock

No price history available.

KvantraRank35
P/E TTMN/A
P/E NTMN/A
Market cap57.68M
KvantraRank?35 / 100
Value
4
Quality
94
Momentum
2
Financialsin USD
20242025TTM2026E
Analyst target
ConsensusLocked
Current6.74
UpsideLocked
LockedLocked
Price consensusLocked
Last year average price targetLocked
Current price6.74
Return PotentialLocked

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked
About

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States of America
Trades inUSD
Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans